Winning Stock Forecast: NSTG Stock Bullish After Q1 Results Expected to Slowly Ease Firm Out of Negative Earnings

Winning Stock Forecast:Image result for nanostring technologies

[Source: Princess Margaret Genomics Centre]

“The journey is never ending. There’s always gonna be growth, improvement, adversity; you just gotta take it all in and do what’s right, continue to grow, continue to live in the moment”
— Antonio Brown

Over the past few weeks, NanoString technologies demonstrated superb stock performance, as seen by their nearly 31% stock growth in a mere 2 weeks. During this time, NSTG stock jumped from $7.29 to $9.86, outperforming the market by 5%. Upon examining the drivers behind this impressive growth that occurred within the past two weeks, the following highlights and updates that shed light on the stock event:

  • NanoString Technologies will release first quarter 2018 financial results after the close of trading on Tuesday, May 8, 2018. Investor expectations are set higher than last year.
  • The company announced the launch of the Breast Cancer 360™ (BC 360) research panel, which provides a unique 360 degree view of a tumor, microenvironment and immune response for breast cancer.
  • NanoString Showcases Groundbreaking Body of Research at the 2018 Annual Meeting of the American Association for Cancer Research


NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release first quarter 2018 financial results after the close of trading on Tuesday, May 8, 2018. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update. The latest earnings release for NanoString Technologies Inc’s was announced in December 2017, which showed that company earnings have become less negative compared to the previous year’s level — great news for investors. However, analysts’ outlook for the upcoming year seems pessimistic, with earnings becoming even more negative, generating -US$71.92M in 2019. However, earnings are expected to move into an upward direction, generating -US$61.01M in 2020, and -US$50.22M in 2021.

Profitability Analysis:

Several important technical indicators of NanoString Technologies, Inc. are now starting to make their way into the trading conversation. Every investor and other stake holder of the firm are most concerned at this time with its profitability. So to answer these concerns, financial ratio analysis and profitability ratios are used as tools to determine the company’s bottom line and its return to its investors.

To start, we can focus on ordinary profitability ratio which covers margins. NSTG has a profit margin of -37.90%. It has gross profit margin ratio of 72.30% for trailing twelve months and operating margin is calculated as -33.20%; these are better detectors to find consistency or positive/negative trends in a firm’s earnings. The company had Return on equity of -129.90% in last 12 months period. Return on assets ratio of the Company was -32.10%. Its return on investment ratio was -0.80% in the trailing 12 months period. The Company’s sales have grown at an average annualized rate of about 38.00% during the past five years. For the past 5 years, The Company’s EPS growth has been nearly 67.80%. Analyst established EPS growth expected to grow of 89.40% for this year and EPS growth for next year is likely to attain at 22.30%. Looking about the past performance history, the company plunged -2.48% for the last five trades and expanded 37.39% in one month period. The stock improved 6.73% during the past three month period and decreased -14.15% in a mere half year. During the yearly overview it downgraded -48.11% and showed 21.02% year to date performance. Therefore, the upper calculated figures are representing the firm’s ability to translate sales dollars into profits at various stages of measurement. The gross margin figure of the firm looks at how well a company controls the cost of its inventory and the manufacturing of its products and subsequently pass on the costs to its consumers.

Following in line of profitability ratio analysis, the second part is stock returns analysis. The returns on investment amplifies the findings found before, as the firm’s ROI concludes as -0.80% — it gives an idea for personal financial decisions, to compare a firm’s profitability or to compare the efficiency of different investments. The returns on assets of the firm is also on noticeable level, as it has ROA of -32.10%, which signifies how profitable a firm is relative to its total assets.

Taking notice on volatility measures, NanoString Technologies, Inc. has noticeable recent volatility credentials; price volatility of stock was 4.15% for a recent week and 5.90% for a month. We might think of historical volatility as the rate of change of the underlying stock price. The higher the level of historical volatility, the more that the stock has moved in recent history. Therefore, theoretically, we will also expect that stock to move in similar degrees into the future, although it’s important to remember that historical volatility does not provide insight into either trend or direction. Although there are multiple ways to calculate historical volatility, the basic underlying idea is essentially the same for each. Historical volatility examines how quickly a stock price or future has moved in the past to predict how far it might move in the future. Investor expectations predict that the firm will publish less-negative results during their earnings release, which is leading to the firm’s increase in stock value. Of course, the firm and investors must be wary of such results, as one good quarter may not indicate total success of the firm, as well as future success. However, it is a nice starting point to the firm’s eventual success.

Analysts expect NSTG  to report $-0.77 EPS on May, 3. They anticipate $0.10 EPS change or 11.49 % from last quarter’s $-0.87 EPS. After having $-0.34 EPS previously, NanoString Technologies’s analysts see 126.47 % EPS growth. The stock increased 3.34% or $0.31 during the last trading session, reaching $9.58. About 187,845 shares traded. The company has declined 64.95% since April 18, 2017 and is downtrending. It has underperformed the S&P500 by 76.50%.

However, in good news, on April 10th, NanoString Tech. announced the launch of the Breast Cancer 360™ (BC 360) research panel. The BC 360 Panel provides a unique 360 degree view of the tumor, microenvironment and immune response. The 770 gene expression panel includes comprehensive and expertly curated content across important breast cancer pathways and contains validated and novel signatures including NanoString’s PAM50 signature for breast cancer subtyping as well as the Tumor Inflammation Signature for determining whether a tumor is inflamed (“hot”) or non-inflamed (“cold”). The BC360 Panel is part of an expanding portfolio of comprehensive cancer research panels for the growing field of translational research and signature development.

“Breast cancer is a complex disease with many distinct subtypes, each having its own unique biology. While cancer research and drug development have historically focused on understanding the biology of the tumor itself, the field is moving toward a more holistic approach that goes beyond the tumor to examine the role that the tumor microenvironment and host immune response play,” said Alessandra Cesano, NanoString’s chief medical officer. “We created the Breast Cancer 360 Panel to anticipate the needs of translational researchers in their quest to understand the implications of heterogeneity in breast cancer for drug development and patient management.”

NasdaqGM:NSTG Future Profit Apr 6th 18

The nCounter™ BC 360 Panel and data analysis service categorize disease heterogeneity using 24 biological signatures including  the foundational PAM50 signature for breast cancer intrinsic subtyping, breast cancer receptor signaling, measures of DNA damage repair deficiency, inhibitory immune signaling and immune cell population abundance. The Panel provides an easy-to-use workflow that allows researchers to go from sample-to-data in 24 hours with less than 30 minutes of hands-on time. The BC 360 Panel is the second in a series of comprehensive cancer research panels, following the launch of the PanCancer Immuno-Oncology (IO) 360™ Panel in the fall of 2017.

The PanCancer IO360 panel consists of 770 genes and is designed to characterize mechanisms of tumor immune evasion and identify targetable therapeutic pathways by leveraging several gene signatures to describe key biological processes. The panel is designed around the Tumor Inflammation Signature (TIS), an 18 gene signature which measures the presence or absence of a peripherally suppressed adaptive immune response within the tumor that enriches for patient response to a variety of  different cancer immunotherapies.

NanoString Showcases Groundbreaking Body of Research at the 2018 Annual Meeting of the American Association for Cancer Research

More than 50 abstracts highlight the diverse capabilities of NanoString’s technology from gene expression profiling to Digital Spatial Profiling. NanoString Technologies, Inc. on April 12th, announced a record number of abstracts that will be presented at the American Association of Cancer Research (AACR) conference to be held April 14-18, 2018, in Chicago, Illinois. “We’re proud of the extent to which our technologies are being showcased at AACR this year, and we are excited about the opportunities for growth as we extend our leadership in biomarker development and precision oncology,” said Brad Gray, president and CEO of NanoString. More than 50 abstracts using NanoString’s technologies will be presented at AACR, including applications such as gene expression profiling in cancer and immuno-therapy using NanoString Panel products such as the PanCancer line and IO 360, high throughput cell line screening with PlexSet™ reagents and highly multiplexed protein quantification using Digital Spatial Profiling.

On April 4th 2018, I Know First issued a bullish 14-day  forecast for NSTG stock. The forecast illustrated a signal of 22.84 and a predictability of 0.27. In accordance with the forecast, NSTG’s stock returned 30.35% over this 2 week period, highlighting the accuracy of the prediction produced by the I Know First algorithm.

I Know First’s Success With NSTG Stock:

Current I Know First subscribers received this bullish NSTG forecast on April 4th 2018. 

To subscribe today click here.

How to interpret this diagram

NanoString Technologies, Inc. (NASDAQ: NSTG), incorporated on June 20, 2003, develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company’s nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Company markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use. The Company’s molecular diagnostic product Prosigna Breast Cancer Assay, or Prosigna, provides an assessment of a patient’s risk of recurrence for breast cancer. As of December 31, 2016, the Company had an installed base of approximately 480 systems, which its customers have used to publish over 1,450 peer-reviewed papers.


Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.